Five-year outcome in immune-mediated scleritis

  • Wolfgang Bernauer
  • Beat Pleisch
  • Matthias Brunner
Inflammatory Disorders



Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis.


Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series.


Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5).


The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.


Scleritis Cornea Keratitis Outcome Inflammation Immunopressive therapy Steroids 


  1. 1.
    Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA (2004) Evaluation of patients with scleritis for systemic disease. Ophthalmology 111:501–506PubMedCrossRefGoogle Scholar
  2. 2.
    Sainz de la Maza M, Foster CS, Jabbur NS (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmology 102:687–692PubMedCrossRefGoogle Scholar
  3. 3.
    Watson PG, Heyreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163–191PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Bernauer W, Ficker LA, Watson PG, Dart JKG (1995) The management of corneal perforations associated with rheumatoid arthritis. Ophthalmology 102:1325–1337PubMedCrossRefGoogle Scholar
  5. 5.
    Sainz del la Maza, Jabbur NS, Foster CS (1993) An analysis of therapeutic decisions for scleritis. Ophthalmology 100:1372–1376CrossRefGoogle Scholar
  6. 6.
    Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS (2012) Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119:43.50PubMedGoogle Scholar
  7. 7.
    Wieringa WG, Sieringa JE, Dam-van Loon NH, Los LI (2013) Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology 120:379–386PubMedCrossRefGoogle Scholar
  8. 8.
    McCluskey PJ, Wakefield D (1996) Scleritis and Episcleritis. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity, 1st edn. Mosby, St. Louis, pp 642–662Google Scholar
  9. 9.
    Arellanes-Garcia L, del Carmen Preciado-Delgadillo M, Graza-Leon M (2011) Refractive changes in patients with autoimmune scleritis. J Ophthalmol Inflamm Infect 1:173–175CrossRefGoogle Scholar
  10. 10.
    Meller D, Böker T (1997) Complications of misdiagnosed and inadequately treated necrotizing scleritis studied by ultrasound biomicroscopy and computerized corneal topography. Int Ophthalmol 21(1):35–37PubMedCrossRefGoogle Scholar
  11. 11.
    Tuft SJ, Watson PG (1991) Progression of scleral disease. Ophthalmology 98:467–471PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Wolfgang Bernauer
    • 1
    • 2
  • Beat Pleisch
    • 1
  • Matthias Brunner
    • 1
  1. 1.OMMA Eye CenterZürichSwitzerland
  2. 2.Department of OphthalmologyUniversity Hospital of ZürichZürichSwitzerland

Personalised recommendations